Hepatitis B: An important public health issue

Journal of Medical Virology

Volumn 61, Issue 3, 2000, Pages 362-366

  Maddrey, Willis C ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis B; Epidemiology; Nucleoside analogue; Treatment; Vaccination

Indexed keywords

ALPHA INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG;

CHRONIC DISEASE; CONFERENCE PAPER; DRUG COST; ENDEMIC DISEASE; ERADICATION THERAPY; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HUMAN; INFECTION PREVENTION; LIVER CIRRHOSIS; NONHUMAN; PREVALENCE; VIRUS TRANSMISSION;

ADULT; ANTIVIRAL AGENTS; ENDEMIC DISEASES; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; WORLD HEALTH;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0034078342     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200007)61:3<362::AID-JMV14>3.0.CO;2-I     Document Type: Conference Paper

References (29)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Alter M. 1996. Epidemiology and disease burden of hepatitis B and C. Antiviral Ther 1(Suppl 3):9-15.
3. Boag F. 1991. Hepatitis B: heterosexual transmission and vaccination strategies. Int J STD AIDS 2:318-324.
4. Chang M-H. 1998. Hepatitis B: long-term outcome and benefits from mass vaccination in children. Acta Gastroenterol Belg 61:210-213.
5. Chang M-H, Chen C-J, Lai M-S, Hsu H-M, Wu T-C, Kong M-S, Liang D-C, Shau W-Y, Chen D-S, for the Taiwan Childhood Hepatoma Study Group. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859.
6. Coleman PJ, McQuillan GM, Moyer LA, Lambert SB, Margolis HS. 1998. Incidence of hepatitis B virus infection in the United States, 1976-1994: estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 178:954-959.
7. Davey S. 1996. State of the world's vaccines and immunisation. Geneva: World Health Organisation. p 76-82.
8. Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M, Brown N, and the US Lamivudine Investigator Group. 1998. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis Be-antigen (HBeAg) seroconversion. Gastroenterology 114:A1235 (Abstract L0148).
9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
10. Dusheiko G. 1999. A pill a day, or two, for hepatitis B? Lancet 353: 1032.
11. Gitlin N. 1997. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 43:1500-1506.
12. Gust ID. 1996. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 38(Suppl 2):S18-S23.
13. Kane MA. 1998. Status of hepatitis B immunisation programmes in 1998. Vaccine 16:3104-3108.
14. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF, for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
15. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, Wu PC. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
16. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745.
17. Liaw YF, Lai CL, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Roman LC, Dent JC, Gray DF. 1998. Two-year lamivudine therapy in chronic hepatitis B infection: results of a placebo controlled multicentre study in Asia. Gastroenterology 114:A1289 (Abstract L0379).
18. Margolis HS, Alter JH, Hadler SC. 1991. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 11:84-92.
19. Mast EE, Alter MJ. 1993. Epidemiology of viral hepatitis: an overview. Semin Virol 4:273-283.
20. Maynard JE. 1990. Hepatitis B: global importance and need for control. Vaccine 8(Suppl):S18-S20.
21. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. 1999. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Pub Health 89:14-18.
22. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC. 1997. Lamivudine therapy for chronic hepatitis B: six-month randomised dose-ranging study. Gastroenterology 113:1258-1263.
23. Rosenberg PM, Dienstag JL. 1999. Therapy with nucleoside analogues for hepatitis B virus infection. Clin Liver Dis 3:349-361.
24. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF, the International Lamivudine Study Group. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46:562-568.
25. Tyrrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Beranek P, Vicary C. 1993. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18:112A (Abstract 224).
26. Vail BA. 1997. Management of chronic viral hepatitis. Am Fam Phys 55:2749-2756.
27. Van Damme P, Tormans G, Beutels P, Van Doorslaer E. 1995. Hepatitis B prevention in Europe: a preliminary economic evaluation. Vaccine 13(Suppl 1):S54-S57.
28. Zuckerman AJ. 1999. More than third of world's population has been infected with hepatitis B virus [letter]. Br Med J 318:1213.
29. Zuckerman AJ. 1996. Progress towards the comprehensive control of hepatitis B. Gut 38(Suppl 2):S1.